Full Motion Sports to develop Energize Pro sports drink
Wild berry flavored athletic based energy drink will be developed as the first flavor of Energize Pro. The company said Energize Pro’s development is based on its existing
Wild berry flavored athletic based energy drink will be developed as the first flavor of Energize Pro. The company said Energize Pro’s development is based on its existing
A supplemental new drug application was submitted to FDA for Promacta (eltrombopag) as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection to permit the
Amyvid loses over half of its radioactivity every two hours because of which it must be distributed directly to imaging centers from the specialized radiopharmacies where it is
The fully-human antibody targets the inhibitory receptor expressed on activated T-cells called PD-1 or programmed death-1. In the dose-ranging study 003, the anti-PD-1 immunotherapy (BMS-936558), showed clinical activity
The 107 patients, with unresectable HCC and had disease progression after first-line therapy or were unable to tolerate the first-line therapy, were randomized in the placebo-controlled, double-blinded study.
The investigators in the GCC Chemical Genomics (GCC-CG) program will have access to Accelrys software, which will be used to support multi-disciplinary collaborative research and training programs for
CRC implemented Browser, Dotmatics’ enterprise query platform, and Vortex, a premium data visualization and analysis tool, to enhance data sharing, communication and increase research output. Cancer Therapeutics CRC
The multicenter, randomized study is designed to evaluate the substitution of Marqibo (Vincristine Sulfate Liposome Injection, VSLI) for standard Vincristine Sulfate Injection (VSI) in the induction, intensification, and
According to the agreement, Nabriva will receive $25m fund to conduct certain development activities related to BC-3781 over the next 12 months. Forest has the exclusive right to
The transaction will have an immaterial impact on Ceradyne’s fully diluted earnings per share during 2012, according to the Ceradyne. Ceradyne vice president and ESK president Thomas Juengling